Evidence map›Paper›PMID 37745326›Full record

ArticlebioRxiv : the preprint server for biology2023

Developmental priming of cancer susceptibility.

Ilaria Panzeri, Luca Fagnocchi, Stefanos Apostle, Megan Tompkins, Emily Wolfrum, Zachary Madaj, Galen Hostetter, Yanqing Liu, Kristen Schaefer, Yang Chih-Hsiang and 8 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Ilaria PanzeriDepartment of Epigenetics, Van Andel Institute, Grand Rapids, MI, USA.
Luca FagnocchiDepartment of Epigenetics, Van Andel Institute, Grand Rapids, MI, USA.
Stefanos ApostleDepartment of Epigenetics, Van Andel Institute, Grand Rapids, MI, USA.
Megan TompkinsVivarium and Transgenics Core, Van Andel Institute, Grand Rapids, MI, USA.
Emily WolfrumBioinformatics and Biostatistics Core, Van Andel Institute, Grand Rapids, MI, USA.
Zachary MadajBioinformatics and Biostatistics Core, Van Andel Institute, Grand Rapids, MI, USA.
Galen HostetterPathology and Biorepository Core, Van Andel Institute, Grand Rapids, MI, USA.
Yanqing LiuDepartment of Epigenetics, Van Andel Institute, Grand Rapids, MI, USA.
Kristen SchaeferDepartment of Epigenetics, Van Andel Institute, Grand Rapids, MI, USA.
Yang Chih-HsiangDepartment of Epigenetics, Van Andel Institute, Grand Rapids, MI, USA.
Alexis BergsmaDepartment of Epigenetics, Van Andel Institute, Grand Rapids, MI, USA.
Anne DrougardDepartment of Epigenetics, Van Andel Institute, Grand Rapids, MI, USA.
Erez DrorDepartment of Epigenetics, Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
PERMUTE
Darrell ChandlerDepartment of Epigenetics, Van Andel Institute, Grand Rapids, MI, USA.
Daniel SchramekCentre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada.
Timothy J TricheDepartment of Epigenetics, Van Andel Institute, Grand Rapids, MI, USA.
J Andrew PospisilikDepartment of Epigenetics, Van Andel Institute, Grand Rapids, MI, USA.

Funding

Master regulators of unexplained variation in disease riskR01HG012444 · NHGRI · VAN ANDEL RESEARCH INSTITUTE · PI NADEAU, JOSEPH H., POSPISILIK, JOHN ANDREW · 2021 to 2025
$9.6M
A Trim28-ERV axis drives phenotypic variation in obesityR01DK132216 · NIDDK · VAN ANDEL RESEARCH INSTITUTE · PI POSPISILIK, JOHN ANDREW, SCHONES, DUSTIN EDWARD · 2023 to 2025
$1.8M
The roles of genetics, hormones, and gender in sexually dimorphic immune responseR01AI171984 · NIAID · VAN ANDEL RESEARCH INSTITUTE · PI KRAWCZYK, CONNIE, PROKOP, JEREMY WILLIAM · 2022 to 2024
$1.4M
Epigenetic control and probabilistic disease programmingR21HG011964 · NHGRI · VAN ANDEL RESEARCH INSTITUTE · PI POSPISILIK, JOHN ANDREW · 2021 to 2021
$523k
NHGRI NIH HHS R01 HG012444NHGRI NIH HHS R21 HG011964NIAID NIH HHS R01 AI171984NIDDK NIH HHS R01 DK132216
6 · The paper itself

Abstract

DNA mutations are necessary drivers of cancer, yet only a small subset of mutated cells go on to cause the disease. To date, the mechanisms that determine which rare subset of cells transform and initiate tumorigenesis remain unclear. Here, we take advantage of a unique model of intrinsic developmental heterogeneity (

Indexed as

Cancer susceptibilitydevelopmentepigenetic heterogeneityphenotypic variationTp53Trim28

Identifiers

PMID37745326
PMCPMC10515831

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.